Show simple item record

dc.contributor.authorSchomaker, M
dc.contributor.authorLeroy, V
dc.contributor.authorWolfs, T
dc.contributor.authorTechnau, KG
dc.contributor.authorRenner, L
dc.contributor.authorJudd, A
dc.contributor.authorSawry, S
dc.contributor.authorAmorissani-Folquet, M
dc.contributor.authorNoguera-Julian, A
dc.contributor.authorTanser, F
dc.contributor.authorEboua, F
dc.contributor.authorNavarro, Maria L
dc.contributor.authorChimbetete, C
dc.contributor.authorAmani-Bosse, C
dc.contributor.authorWarszawski, J
dc.contributor.authorPhiri, S
dc.contributor.authorN’Gbeche, S
dc.contributor.authorCox, V
dc.contributor.authorKoueta, F
dc.contributor.authorGiddy, J
dc.contributor.authorSygnaté-Sy, H
dc.contributor.authorRaben, D
dc.contributor.authorChêne, G
dc.contributor.authorDavies, MA
dc.date.accessioned2016-07-29T13:15:14Z
dc.date.available2016-07-29T13:15:14Z
dc.date.issued2016-06-24
dc.identifier.citationOptimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe 2016:dyw097 International Journal of Epidemiologyen
dc.identifier.issn0300-5771
dc.identifier.issn1464-3685
dc.identifier.doi10.1093/ije/dyw097
dc.identifier.urihttp://hdl.handle.net/10144/617740
dc.description.abstractBackground: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents. Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients, aged 1-16 years at enrolment, from 19 cohorts in Europe, Southern Africa and West Africa, were included. We compared mortality and growth outcomes for different ART initiation criteria, aligned with previous and recent World Health Organization criteria, for 5 years of follow-up, adjusting for all measured baseline and time-dependent confounders using the g-formula. Results: Median (1st;3rd percentile) CD4 count at baseline was 676 cells/mm3 (394; 1037) (children aged ≥ 1 and < 5 years), 373 (172; 630) (≥ 5 and < 10 years) and 238 (88; 425) (≥ 10 and < 16 years). There was a general trend towards lower mortality and better growth with earlier treatment initiation. In children < 10 years old at enrolment, by 5 years of follow-up there was lower mortality and a higher mean height-for-age z-score with immediate ART initiation versus delaying until CD4 count < 350 cells/mm3 (or CD4% < 15% or weight-for-age z-score < -2) with absolute differences in mortality and height-for-age z-score of 0.3% (95% confidence interval: 0.1%; 0.6%) and -0.08 (-0.09; -0.06) (≥ 1 and < 5 years), and 0.3% (0.04%; 0.5%) and -0.07 (-0.08; -0.05) (≥ 5 and < 10 years). In those aged > 10 years at enrolment we did not find any difference in mortality or growth with immediate ART initiation, with estimated differences of -0.1% (-0.2%; 0.6%) and -0.03 (-0.05; 0.00), respectively. Growth differences in children aged < 10 years persisted for treatment thresholds using higher CD4 values. Regular follow-up led to better height and mortality outcomes. Conclusions: Immediate ART is associated with lower mortality and better growth for up to 5 years in children < 10 years old. Our results on adolescents were inconclusive.
dc.language.isoenen
dc.publisherOxford University Pressen
dc.relation.urlhttp://ije.oxfordjournals.org/lookup/doi/10.1093/ije/dyw097en
dc.rightsPublished by Oxford University Press Archived on this site with kind permission from Oxford University Press and the International Epidemiological Associationen
dc.titleOptimal Timing of Antiretroviral Treatment Initiation in HIV-Positive Children and Adolescents: a Multiregional Analysis from Southern Africa, West Africa and Europeen
dc.identifier.journalInternational Journal of Epidemiologyen
refterms.dateFOA2019-03-04T12:48:44Z
html.description.abstractBackground: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents. Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients, aged 1-16 years at enrolment, from 19 cohorts in Europe, Southern Africa and West Africa, were included. We compared mortality and growth outcomes for different ART initiation criteria, aligned with previous and recent World Health Organization criteria, for 5 years of follow-up, adjusting for all measured baseline and time-dependent confounders using the g-formula. Results: Median (1st;3rd percentile) CD4 count at baseline was 676 cells/mm3 (394; 1037) (children aged ≥ 1 and < 5 years), 373 (172; 630) (≥ 5 and < 10 years) and 238 (88; 425) (≥ 10 and < 16 years). There was a general trend towards lower mortality and better growth with earlier treatment initiation. In children < 10 years old at enrolment, by 5 years of follow-up there was lower mortality and a higher mean height-for-age z-score with immediate ART initiation versus delaying until CD4 count < 350 cells/mm3 (or CD4% < 15% or weight-for-age z-score < -2) with absolute differences in mortality and height-for-age z-score of 0.3% (95% confidence interval: 0.1%; 0.6%) and -0.08 (-0.09; -0.06) (≥ 1 and < 5 years), and 0.3% (0.04%; 0.5%) and -0.07 (-0.08; -0.05) (≥ 5 and < 10 years). In those aged > 10 years at enrolment we did not find any difference in mortality or growth with immediate ART initiation, with estimated differences of -0.1% (-0.2%; 0.6%) and -0.03 (-0.05; 0.00), respectively. Growth differences in children aged < 10 years persisted for treatment thresholds using higher CD4 values. Regular follow-up led to better height and mortality outcomes. Conclusions: Immediate ART is associated with lower mortality and better growth for up to 5 years in children < 10 years old. Our results on adolescents were inconclusive.


Files in this item

Thumbnail
Name:
Schomaker et al - 2016 - Optimal ...
Size:
1.222Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record